BelančićAStrbadTKučan ŠtiglićMVitezićD.Switching from nusinersen to risdiplam: a croatian real-world experience on effectiveness and safety. J Pers Med. 2024;14(3):244. doi: 10.3390/jpm14030244
FinkelRSChiribogaCAVajsarJ, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8
4.
MercuriEDarrasBTChiribogaCA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625-635. doi: 10.1056/NEJMoa1710504
5.
KakazuJWalkerNLBabinKC, et al. Risdiplam for the use of spinal muscular atrophy. Orthop Rev (Pavia). 2021;13(2):25579. doi: 10.52965/001c.25579
6.
MercuriEKirschnerJGoemansN, et al. Risdiplam in type 1, 2, and 3 spinal muscular atrophy: a randomized, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2021;20(8):604-614.
